26 June 2024
BerGenBio ASA: Grant of share options
Bergen, Norway, 26 June 2024 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees.
The annual general meeting in the Company on 23 May 2024 approved the share option program and authorised the board of directors of the Company to issue up to 3,908,711 share options to the Company’s employees as part of a long-term incentive plan.
Options granted under the share option program will normally vest equally over a three-year period from the date of grant and each option, when exercised, will give the right to receive one share in the Company at a fixed strike price set at time of grant. Options granted under the share option program expire eight years after grant date.
A total of 1,315,000 share options were granted, equal to 3.3% of total issued shares in the Company and 3.1% on a fully dilutive basis including all outstanding options. The strike price for this grant is NOK 11.226 per option equal to the volume weighted average share price the last 14 days before the grant.
Share options granted in 2023 or earlier have been adjusted because of the reverse share split approved by the Annual General Meeting 23 May 2024. Accordingly, total number of options have been divided by 100 and strike price multiplied by 100. The total number of options outstanding after the adjustment and before today’s grant are 1,149,765 of which 21,672 are vested and 1,128,093 are not vested.
Following today’s grant the total issued share options equals 6.3% of the total issued shares in the Company and 5.9% on a fully dilutive basis. Total options outstanding after this grant are 2,464,765. Of this, 21,672 share options are vested and 2,443,093 not vested.
Of the total grant the following were granted to primary insiders (total holdings of share options following this grant):
Martin Olin – CEO: 350,000 (599,501)
Rune Skeie – CFO: 165,000 (288,981)
Cristina Oliva – CMO: 165,000 (287,001)
In total 680,000 share options were granted to primary insiders.
The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The board considers the option program terms and allocation to be at the market for comparable peers.
-End-
Contacts
Martin Olin
CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Jan Lilleby
jl@lillebyfrisch.no
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visitwww.bergenbio.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
